News
6hon MSN
Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.
The astraszenecaglobal.xyz scam is abusing the real pharmaceutical giant’s name to run a fake investment scheme targeting ...
23mon MSN
IRB Infrastructure. IRB Infrastructure recorded a 9% year-on-year increase in toll revenue, reaching 581 crore in May 2025.
Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...
Sanofi boosts Beyfortus output for RSV season while Dupixent trial shows strong eczema relief in patients with skin of color.
17h
GlobalData on MSNEC approves AstraZeneca’s acalabrutinib combo for CLLThe EC has granted approval for a fixed-duration regimen of AstraZeneca's Calquence (acalabrutinib) plus venetoclax.
Drugmaker AstraZeneca has agreed to pay $50.9 million to settle a class action lawsuit in U.S. court accusing the company of ...
AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition.
Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...
AstraZeneca PLC closed 19.58% short of its 52-week high of £133.88, which the company reached on September 3rd.
IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, announced results of a collaborative research program between IonQ, AstraZeneca, Amazon Web Services (AWS), and NVIDIA ...
Bangalore: AstraZeneca Pharma India has announced the appointment of Praveen Rao Akkinepally as the new Managing Director of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results